SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-109836
Filing Date
2018-04-06
Accepted
2018-04-06 14:36:33
Documents
12
Period of Report
2018-04-25
Effectiveness Date
2018-04-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A d548435ddef14a.htm DEF 14A 116825
2 GRAPHIC g5484351a.jpg GRAPHIC 55121
3 GRAPHIC g5484351b.jpg GRAPHIC 44289
4 GRAPHIC g5484351c.jpg GRAPHIC 8980
5 GRAPHIC g5484351d.jpg GRAPHIC 2048
6 GRAPHIC g5484351f.jpg GRAPHIC 1518
7 GRAPHIC g5484351g.jpg GRAPHIC 46666
8 GRAPHIC g5484352b.jpg GRAPHIC 1363
9 GRAPHIC g5484352c.jpg GRAPHIC 1518
10 GRAPHIC g548435g23v14.jpg GRAPHIC 11549
11 GRAPHIC g548435img8.jpg GRAPHIC 1564
12 GRAPHIC g548435newimg1.jpg GRAPHIC 20260
  Complete submission text file 0001193125-18-109836.txt   388105
Mailing Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017
Business Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017 (813) 864-4523
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33958 | Film No.: 18742902
SIC: 2834 Pharmaceutical Preparations